- Home
- MDWD vs ONCH Comparison
MDWD vs ONCH Comparison
Compare MDWD & ONCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDWD
- ONCH
- Stock Information
- Founded
- MDWD 2000
- ONCH 2024
- Country
- MDWD Israel
- ONCH United States
- Employees
- MDWD N/A
- ONCH N/A
- Industry
- MDWD Medicinal Chemicals and Botanical Products
- ONCH
- Sector
- MDWD Health Care
- ONCH
- Exchange
- MDWD Nasdaq
- ONCH Nasdaq
- Market Cap
- MDWD 195.2M
- ONCH 223.4M
- IPO Year
- MDWD 2014
- ONCH 2025
- Fundamental
- Price
- MDWD $17.66
- ONCH $10.35
- Analyst Decision
- MDWD Strong Buy
- ONCH
- Analyst Count
- MDWD 2
- ONCH 0
- Target Price
- MDWD $35.00
- ONCH N/A
- AVG Volume (30 Days)
- MDWD 60.7K
- ONCH 30.3K
- Earning Date
- MDWD 11-20-2025
- ONCH 01-01-0001
- Dividend Yield
- MDWD N/A
- ONCH N/A
- EPS Growth
- MDWD N/A
- ONCH N/A
- EPS
- MDWD N/A
- ONCH N/A
- Revenue
- MDWD $19,858,000.00
- ONCH N/A
- Revenue This Year
- MDWD $21.39
- ONCH N/A
- Revenue Next Year
- MDWD $23.01
- ONCH N/A
- P/E Ratio
- MDWD N/A
- ONCH N/A
- Revenue Growth
- MDWD N/A
- ONCH N/A
- 52 Week Low
- MDWD $14.14
- ONCH $10.18
- 52 Week High
- MDWD $22.51
- ONCH $10.63
- Technical
- Relative Strength Index (RSI)
- MDWD 42.31
- ONCH N/A
- Support Level
- MDWD $17.50
- ONCH N/A
- Resistance Level
- MDWD $18.58
- ONCH N/A
- Average True Range (ATR)
- MDWD 0.60
- ONCH 0.00
- MACD
- MDWD -0.13
- ONCH 0.00
- Stochastic Oscillator
- MDWD 2.88
- ONCH 0.00
About MDWD MediWound Ltd.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.
About ONCH 1RT Acquisition Corp. Class A Ordinary Share
1RT Acquisition Corp is a blank check company.